Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
  • Challenge: Minimising immuno-oncology toxicity

By enabling the collection of directly comparable datasets from multiple disease-specific sample collections, Oxford Cancer is extending multi-omic analysis of tissue and the microbiome from checkpoint inhibitor-treated patients with those with colitis. Oxford researchers are undertaking cross-tissue comparisons of immune related adverse events in collaboration with the CARTOGRAPHY consortium that will carry out single cell and microbiome mapping of inflammatory diseases in the gut, joints, liver and skin in partnership with Janssen Pharmaceuticals. In collaboration with national partners we will establish a national dataset with germline sequencing of patients that experience toxicity to identify risk factors to incorporate into the immune-therapy care pathway. When interpreted in the context of known immune mechanisms, germline risk factors could also indicate early (or prophylactic) deployment of adjunct therapies.